ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tislelizumab

Also written as “Tislelizumab”, “BGB-A317” and “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Carcinoma, Hepatocellular · Stomach Neoplasms · Hodgkin Disease, led by 21 companies.

Drug pageTislelizumab: every studyMany companies study it; this page follows only the 74 they lead. All 434 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Nov 27, 201774 company-led studies, 20 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicinesits history only539 open or runningphase 3since Nov 27, 2017Mar 26, 2015Nov 2026phase 2 · NCT03736889
RemeGenits history only22 open or runningphase 3since Apr 17, 2025Apr 17, 2025May 15, 2028phase 3 · NCT06944496
Antengeneits history only10 open or runningphase 2since May 25, 2020May 25, 2020none ahead
Beijing Aosaikang Pharmaceuticalits history only11 open or runningphase 2since Nov 21, 2022Nov 21, 2022none ahead
Beijing Biostar Pharmaceuticalsits history only11 open or runningphase 2since Sep 18, 2026Sep 18, 2026Sep 20, 2028phase 2 · NCT07842276
BriaCell Therapeuticsits history only11 open or runningphase 2since Jun 11, 2024Jun 11, 2024none ahead
Bristol-Myers Squibb10 open or runningphase 3since Nov 9, 2018Nov 9, 2018none ahead
Changchun GeneScience Pharmaceuticalits history only10 open or runningphase 1since Jun 16, 2022Jun 16, 2022none ahead
HUTCHMEDits history only10 open or runningphase 2since Sep 23, 2020Sep 23, 2020none ahead
Immix Biopharmaits history only11 open or runningphase 2since Jan 4, 2023Jan 4, 2023none ahead

Also a collaborator on its studies: Myriad Genetic Laboratories.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2017Named tislelizumabINNProposed as its International Nonproprietary Name in WHO's List 117
  2. Nov 9, 2018First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03745222 · 1 enrolled · United States, Belgium, Canada and more

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The one study Bristol-Myers Squibb leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03745222Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more3TerminatedJun 26, 20191

How it is read

Names in the registry

  • “Tislelizumab”, 57 entries
  • “BGB-A317”, 2 entries
  • “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”, 1 entry
  • “Tislelizumab (BGB-A317)”, 1 entry
  • “Subcutaneous Tislelizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.